Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

What Goes Up … US FDA Expects 2016 NME Approval Total To Come Down

08 Nov 2016

• By Derrick Gingery

Related Content

‘Breakthrough Therapy’ Designations

22 Feb 2016

Biosimilars Reviews Could Be Extended Two Months In BsUFA II

22 Apr 2016

FDA New Drug Approval Count May Fall Back To Earth In 2016

18 Jul 2016

Surge In Applications Triggers User Fee Inflation

10 Aug 2015

FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds

21 Jul 2016

User Fee Extensions Are Key To CDER's First Cycle Review Success

18 Jan 2016

First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?

06 May 2013

Additional Topics

United States Approvals Drug Review Regulation FDA BioPharmaceutical

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.